OakChart

Serina Therapeutics Inc

SERHealthcare·Biotechnology·USA·Nano·AMEX·Nov 11 • 3:59 PM ET

1.50+0.07 (4.90%)
2026-11-11 22:22 CET
Market cap
36.32 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-23.82 USD m
Free cash flow, TTM
-21.20 USD m
EPS diluted, TTM
-1.88
P/E
-
Compare

Price

SER against its 20, 50 and 200-day averages
2050200missearnings
1.002.003.00572K1.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SERclose 1.5020-day 1.6850-day 1.99200-day 2.041.5052w low

65.2% under the 52-week high of 4.31 on 11 Nov 2025. 52-week low 1.14 on 6 Nov 2026. Last 15 sessions, 123.7% high to low

Volume 0.24× normal · the line is the 50-bar volume average

Profile

SER
52-week range, 11% of the way up
1.144.31

Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley in 2006 and is headquartered in Huntsville, AL.

Employees16
IPONov 29, 2018
Beta1.31
ATR, 14d0.25
Rel volume0.24
Short float0.38%
Insider own51.20%
Inst own9.94%

Snapshot

6 groups

Valuation

Index-
Market Cap38.10M
Enterprise Value18.29M
Income-23.82M
Sales0.00M
Book/sh0.74
Cash/sh0.91
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees16
IPONov 29, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.03
P/C1.65
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio6.65
Current Ratio6.65
Debt/Eq0.17
LT Debt/Eq0.17
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.88
EPS next Y-1.15
EPS next Q-0.34
EPS this Y17.35%
EPS next Y26.95%
EPS next 5Y18.02%
EPS past 3/5Y41.84% 28.41%
Sales past 3/5Y- 19.21%
EPS Y/Y TTM67.71%
Sales Y/Y TTM-
EPS Q/Q15.42%
Sales Q/Q-100.00%
EarningsAug 13 AMC
EPS/Sales Surpr.-17.95% -

Ownership

Insider Own51.20%
Insider Trans0.34%
Inst Own9.94%
Inst Trans1.91%
ROA-121.85%
ROE-206.26%
ROIC-96.52%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-10.74%
SMA50-24.61%
SMA200-26.46%
Trades-

Technical

Shs Outstand25.40M
Shs Float12.40M
Short Float0.38%
Short Ratio0.62
Short Interest0.05M
52W High4.31 -65.20%
52W Low1.14 31.58%
Volatility19.33% 17.79%
ATR (14)0.25
RSI (14)37.79
Beta1.31
Rel Volume0.24
Avg Volume75.72K
Volume17,884

Performance

Perf Week-11.24%
Perf Month-17.58%
Perf Quarter-47.37%
Perf Half Y-3.85%
Perf YTD-21.59%
Perf Year-63.24%
Perf 3Y-92.81%
Perf 5Y-94.79%
Perf 10Y-
Recom1.00
Target Price9.50
Prev Close1.43
Price1.50
Change %4.90%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Jul 01, 2026InitiatedBBTIG ResearchBuy$8+433.3%
Jul 14, 2025InitiatedHH.C. WainwrightBuy$15+900.0%

Peers

Mkt cap
TickerCompanyMkt cap
GANXGain Therapeutics Inc48.45M
ANVSAnnovis Bio Inc36.41M
ATHEAlterity Therapeutics Ltd ADR44.12M
CRVOCervoMed Inc26.78M
VYGRVoyager Therapeutics Inc109.53M
IKTInhibikase Therapeutics Inc227.44M
VANIVivani Medical Inc101.93M
PMNProMIS Neurosciences Inc33.72M
ADXNAddex Therapeutics Ltd ADR3.02M
BIVIBioVie Inc13.51M

Insider trading

latest 14 of 51
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Brannan Stephen K.DirectorJul 07 '26Buy2.031,0002,0301,000Jul 09 12:05 PM
Venkatesan JayDirectorMay 22 '26Buy1.785891,048589Jun 22 07:15 PM
WILSON KAREN JDirectorJun 11 '26Buy1.755,1008,9005,100Jun 15 10:31 AM
WILSON KAREN JDirectorJun 12 '26Buy1.775,0008,85010,100Jun 15 10:31 AM
WILSON KAREN JDirectorMay 22 '26Buy1.9310,00019,30020,000May 26 04:26 PM
WILSON KAREN JDirectorMay 21 '26Buy1.7710,00017,70010,000May 26 04:26 PM
Marshall Richard PeterDirectorMay 19 '26Buy1.6512,18320,10212,183May 22 04:59 PM
Moreadith RandallChief Scientific OfficerMar 23 '26Option Exercise0.066,5003906,500Mar 24 07:24 PM
Moreadith RandallChief Scientific OfficerMar 23 '26Sale2.866,50018,5680Mar 24 07:24 PM
Moreadith RandallChief Scientific OfficerMar 19 '26Option Exercise0.0639,0002,34039,000Mar 20 02:20 PM
Moreadith RandallChief Scientific OfficerMar 19 '26Sale2.5039,00097,5000Mar 20 02:20 PM
Moreadith RandallChief Scientific OfficerFeb 02 '26Option Exercise0.066,5003906,500Feb 03 12:35 PM
Moreadith RandallChief Scientific OfficerFeb 02 '26Sale3.036,50019,6800Feb 03 12:35 PM
Moreadith RandallChief Scientific OfficerJan 28 '26Option Exercise0.066,5003906,500Jan 29 12:54 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 136
  • Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress" (GlobeNewswire) -5.19%
  • Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire) -11.20%
  • Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2 (GlobeNewswire)
  • Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
  • Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease (GlobeNewswire)
  • Serina Therapeutics Appoints Farrell Simon to its Board of Directors (GlobeNewswire)
  • Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease (GlobeNewswire) +10.00%
  • Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) +10.26%
  • Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit (GlobeNewswire)
  • Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan (GlobeNewswire)
  • Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +24.69% -13.86%
  • Serina Therapeutics to Present at the 38th Annual Roth Conference (GlobeNewswire) -22.86%
  • Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease (GlobeNewswire) +93.75%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.550-0.466-0.5500.000.002
2026Q12026-05-14-0.580-0.440-0.5760.000.001
2025Q42026-03-25-0.310-0.500-0.3130.000.001
2025Q32025-11-13-0.450-0.530-0.4440.000.002
2025Q22025-08-11-0.660-0.425-0.6450.130.002
2025Q12025-05-08-0.490-0.620-0.4930.000.001
2024Q42025-03-24-1.1300.420-0.000.001
2024Q32024-11-12--0.1310.01--
2024Q22024-08-09--0.5120.05--
2024Q12024-05-14---3.382---
2023Q32023-11-14---5.0050.07--
2023Q22023-08-14---2.474---
2023Q12023-05-12---3.0370.01--
2022Q42023-03-31---2.5050.01--
2022Q32022-11-10---2.257---
2022Q22022-08-12---2.4270.01--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-1.5100.240-1.5140.060.10
2025FY-1.910-2.080-0.130.13
2026FY--1.579--0.00
2027FY--1.153--0.00
2028FY--1.053---
2029FY--1.139---
2030FY--1.220---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-141000.000.000.00
2026Q3S2026-08-131000.000.000.00
2026Q3S2026-05-151000.000.000.00
2026Q3S2026-03-261000.000.000.00
2026Q3S2025-12-051000.000.000.00
2026Q3S2025-11-132000.000.000.00
2026Q3S2025-11-112000.000.000.00
2026Q3S2025-11-102000.000.000.00
2026Q3S2025-11-092000.000.000.00
2026Q3S2025-11-082000.000.000.00
2026Q3S2025-11-072000.000.000.00
2026Q3S2025-11-062000.000.000.00
2026Q3S2025-11-052000.000.000.00
2026Q3S2025-11-042000.000.000.00

Estimate history

EPS, annual-6.459-7.557-11.469-10.144-8.053-9.6970.728-1.514-1.907-1.8775
Period201720182019202020212022202320242025TTM
EPS, quarterly-3.3820.5120.131-0.493-0.645-0.444-0.313-0.576-0.545
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual1.4041.3961.7280.0540.0403.1530.0560.130
Period201720182019202020212022202320242025TTM
Sales, quarterly0.0050.0510.01400.130000
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual1.0191.0191.071.0721.0791.0792.419.42210.76725.4
Period201720182019202020212022202320242025MRQ
Shares, quarterly8.4148.7928.8929.93210.14510.54310.76714.89925.4
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.130.063.150.000.040.051.731.40
Cost of Goods Sold Incl. D&A0.080.090.190.090.140.151.281.000.84
Gross Profit-0.080.04-0.143.06-0.14-0.11-1.230.730.56
Selling, General and Administrative Excl. Other25.5924.0716.916.196.868.039.1813.2911.00
Research and Development13.9913.077.482.390.891.323.585.355.35
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-25.66-24.02-17.05-3.13-7.01-8.14-10.41-12.56-10.45
Interest Expense0.600.210.530.563.331.100.40-0.00
Unusual Expense-5.76-4.26-6.14-8.67-3.08-0.44-0.000.80
Net Income Before Taxes-21.16-19.20-11.215.27-10.52-8.58-10.40-12.24-7.73
Income Taxes0.030.020.000.000.000.000.000.150.00
Consolidated Net Income-21.18-19.21-11.215.27-10.52-8.58-10.40-12.38-7.73
Net Income From Continuing Operations-21.18-19.18-11.145.27-10.46-8.58-10.39-12.15-7.50
Net Income-23.82-19.44-11.145.27-10.46-8.68-10.87-12.15-7.50
EPS (Recurring)-1.70-2.20-2.10-0.10-11.69-8.34-10.14-11.47-6.99
EPS (Basic, Before Extraordinaries)-1.88-1.91-1.512.36-9.70-8.05-10.14-11.47-7.56
EPS (Diluted)-1.88-1.91-1.510.73-9.70-8.05-10.14-11.47-7.56
EBITDA-25.59-23.94-16.85-3.04-6.88-8.01-9.15-11.61-9.91
Non-Operating Income (Expense)-0.660.780.230.28-3.250.220.410.323.51
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.653.002.600.030.761.000.931.391.47
Price To Sales Ratio-149.95658.3731.57-1,032.391,060.3139.2674.78
Gross Margin-34.62-246.4397.15--275.00-2,272.2242.2239.76
Operating Margin--18,478.46-30,442.86-99.24--20,357.50-19,272.22-726.79-748.21
Net Margin--14,950.77-19,894.64167.11--21,687.50-20,120.37-703.36-537.39
Shares Outstanding25.4010.779.422.411.081.081.071.071.02
Market Capitalization36.3236.3244.5514.6120.9441.3657.2968.52107.13

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q32024Q2
Total Revenue0.000.000.000.000.130.000.010.05
Cost of Goods Sold Incl. D&A0.020.020.020.020.020.020.060.06
Gross Profit-0.02-0.02-0.02-0.020.11-0.02-0.04-0.01
Selling, General and Administrative Excl. Other6.776.266.186.385.675.845.273.86
Research and Development3.803.183.383.633.132.952.361.54
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.78-6.28-6.21-6.39-5.57-5.86-5.31-3.87
Interest Expense0.200.190.200.010.01-0.020.24
Unusual Expense-0.40-1.13-3.19-1.040.96-0.99-6.67-9.29
Net Income Before Taxes-6.36-6.89-3.32-4.59-6.46-4.821.385.18
Income Taxes0.000.010.020.000.000.000.000.00
Consolidated Net Income-6.36-6.90-3.34-4.59-6.46-4.821.385.18
Net Income From Continuing Operations-6.36-6.90-3.34-4.58-6.45-4.811.415.20
Net Income-8.93-6.93-3.37-4.58-6.45-4.811.415.20
EPS (Recurring)-0.56-0.64-0.52-0.51-0.58-0.56-0.30-0.13
EPS (Basic, Before Extraordinaries)-0.55-0.58-0.31-0.44-0.64-0.490.160.61
EPS (Diluted)-0.55-0.58-0.31-0.44-0.64-0.490.130.51
EBITDA-6.77-6.26-6.18-6.38-5.54-5.84-5.26-3.81
Non-Operating Income (Expense)0.23-1.56-0.100.760.070.050.04-0.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.050.850.751.000.890.961.100.46
Price To Sales Ratio-179.78158.44---570.83543.60
Gross Margin----83.08--300.00-11.76
Operating Margin-----4,280.77--37,942.86-7,580.39
Net Margin-----4,960.00-10,071.4310,203.92
Shares Outstanding25.4014.9010.7710.5410.149.938.898.79
Market Capitalization36.3223.8920.4054.9461.4056.3259.4280.61

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments3.063.677.620.650.580.532.356.717.38
Short Term Receivables0.000.000.000.000.030.330.360.130.11
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.022.000.001.801.621.431.341.010.11
Total Current Assets6.085.687.622.452.232.284.057.857.59
Net Property, Plant & Equipment0.841.051.350.000.000.001.130.090.13
Total Investments and Advances0.000.000.000.050.050.050.000.000.00
Long-Term Note Receivable--10.55------
Intangible Assets0.000.000.000.740.871.592.152.711.87
Deferred Tax Assets0.17--------
Other Assets0.030.000.000.000.000.000.110.020.04
Total Assets7.126.728.973.243.153.927.4410.679.63
Short Term Debt Incl. Current Port. of LT Debt0.000.190.257.657.142.400.430.000.00
Accounts Payable1.930.740.580.570.190.760.420.150.07
Other Current Liabilities1.631.430.581.861.632.202.452.291.24
Total Current Liabilities3.562.371.4110.088.975.363.302.441.31
Long Term Debt3.140.273.4410.486.063.901.530.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.17--------
Other Liabilities0.283.580.000.000.000.060.000.000.00
Total Liabilities7.166.224.8620.5615.039.324.832.441.31
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value4.940.0036.400.000.000.000.000.000.00
Common Equity-4.980.64-32.29-17.21-11.83-5.122.227.457.28
Total Shareholders Equity-0.040.644.11-17.21-11.83-5.122.227.457.28
Accumulated Minority Interest0.00-0.130.00-0.10-0.04-0.280.400.781.04
Total Equity-0.040.514.11-17.32-11.88-5.402.628.238.32
Total Liabilities & Stockholders Equity7.126.728.973.243.153.927.4410.679.63
Book Value Per Share-0.460.07-13.40-15.95-10.97-4.772.077.317.15
Tangible Book Value Per Share-0.460.07-13.40-16.64-11.77-6.260.064.655.31
Full-Time Employees16134910111712-
Price to Book Ratio1.94-3.23-0.53-1.39-3.50-11.2030.8914.3910.50
Return on Assets-277.08-119.2386.31-327.19-242.38-182.88-134.20-73.90-102.38
Return on Equity-6,351.66-364.68-----251.51-101.88-
Return on Invested Capital-617.78-1,225.6369.74----324.45-100.74-90.38
Quick Ratio1.712.405.390.240.250.431.233.225.79
Current Ratio1.712.405.390.240.250.431.233.225.79

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-21.18-19.21-11.215.27-10.52-8.58-10.40-12.38-7.73
Depreciation0.080.070.190.090.130.131.250.950.54
Other Funds (Non Cash)0.41-0.28-2.81-7.924.121.481.591.68-1.01
Funds from Operations-20.70-19.43-13.82-2.56-6.27-6.97-7.56-9.75-8.21
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.441.47-3.320.080.33-0.88-0.26-0.410.21
Cash from Operating Activities-21.14-17.95-17.14-2.48-5.94-7.86-7.82-10.16-8.00
Capital Expenditures-0.07-0.06-0.02-0.500.000.00-0.02-0.64-1.89
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.470.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.353.21
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.353.21
Other Uses0.000.000.000.000.00-0.050.00-0.070.00
Other Sources0.000.000.000.000.000.250.00-0.01
Cash from Investing Activities-0.07-0.06-0.02-0.500.000.67-0.02-0.361.33
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock33.2712.5010.000.010.000.500.004.506.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock33.2712.5010.000.010.000.500.004.506.00
Proceedsfrom Stock Options12.1712.480.000.000.000.500.000.000.00
Issuance or Reduction of Debt, Net4.914.912.8810.056.007.005.961.760.00
Change in Long Term Debt4.914.912.8810.056.007.005.531.760.00
Issuance of Long Term Debt4.914.913.0410.106.007.005.541.800.00
Reduction of Long Term Debt0.000.00-0.17-0.050.000.00-0.01-0.040.00
Net Financing Active Other Cash Flow0.000.000.340.000.00-0.250.000.000.00
Other Financing Activities Uses0.000.000.000.00--0.25--0.00
Cash from Financing Activities38.1817.4113.2110.076.007.255.966.266.00
Exchange Rate Effect--0.01---0.000.000.000.00
Net Change in Cash16.98-0.62-3.957.090.060.06-1.88-4.25-0.67
Free Cash Flow-21.20-18.01-17.16-2.98-5.94-7.86-7.84-10.80-8.02
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments23.0224.533.068.626.044.27
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.011.953.022.881.951.49
Total Current Assets25.0326.476.0811.507.995.75
Net Property, Plant & Equipment0.760.800.840.890.950.98
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets--0.17---
Other Assets0.030.030.030.020.000.00
Total Assets25.8127.307.1212.418.946.73
Short Term Debt Incl. Current Port. of LT Debt0.000.000.003.050.180.18
Accounts Payable1.862.831.932.731.711.19
Other Current Liabilities1.903.511.633.011.680.98
Total Current Liabilities3.766.343.568.793.562.35
Long Term Debt3.213.173.140.150.180.23
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.17---
Other Liabilities0.110.160.281.883.552.59
Total Liabilities7.089.677.1610.827.295.17
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.004.944.944.944.940.00
Common Equity18.7312.69-4.98-3.18-3.141.70
Total Shareholders Equity18.7317.63-0.041.761.801.70
Accumulated Minority Interest0.000.000.00-0.17-0.16-0.14
Total Equity18.7317.63-0.041.591.651.56
Total Liabilities & Stockholders Equity25.8127.307.1212.418.946.73
Book Value Per Share0.740.85-0.46-0.30-0.310.17
Tangible Book Value Per Share0.740.85-0.46-0.30-0.310.17
Full-Time Employees--16---
Price to Book Ratio1.942.28-6.34-17.3335.97-3.66
Return on Assets-121.85-124.99----
Return on Equity-206.26-220.05----
Return on Invested Capital-28.97-33.17-107.44-240.30-324.51-249.64
Quick Ratio6.654.181.711.312.242.45
Current Ratio6.654.181.711.312.242.45

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-6.36-6.90-3.34-4.59-6.46-4.82
Depreciation0.020.020.020.020.020.02
Other Funds (Non Cash)0.911.80-1.63-0.671.990.03
Funds from Operations-5.43-5.08-4.95-5.25-4.46-4.78
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.250.51-1.091.400.710.46
Cash from Operating Activities-6.68-4.57-6.03-3.85-3.75-4.32
Capital Expenditures-0.03-0.030.00-0.01-0.050.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.03-0.030.00-0.01-0.050.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.000.000.00
Change in Capital Stock5.2026.060.481.535.574.92
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5.2026.060.481.535.574.92
Proceedsfrom Stock Options-15.8826.050.481.525.574.92
Issuance or Reduction of Debt, Net0.000.000.004.910.000.00
Change in Long Term Debt0.000.004.910.000.000.00
Issuance of Long Term Debt0.000.004.910.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities5.2026.060.486.445.574.92
Exchange Rate Effect0.010.01-0.01---
Net Change in Cash-1.5021.47-5.562.581.770.59
Free Cash Flow-6.71-4.59-6.03-3.86-3.80-4.32

Revenue breakdown

Grant Revenues2024: 56.00K
Total Pharmaceutical Preparations revenue2025: 130.00K
United States2024: 56.00K 2025: 130.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.38%0.0M12.4M69.38K
2026-10-150.35%0.0M12.4M64.22K
2026-09-300.46%0.1M12.4M67.10K
2026-09-150.96%0.1M12.4M60.13K
2026-08-312.08%0.1M3.4M77.60K
2026-08-144.32%0.1M3.4M85.23K
2026-07-3111.20%0.2M2.0M85.57K
2026-07-1514.30%0.3M2.0M94.74K
2026-06-302.74%0.3M10.4M137.73K
2026-06-153.61%0.4M10.6M3.21M
2026-05-293.56%0.3M9.7M3.24M
2026-05-153.80%0.3M8.5M3.24M
2026-04-303.51%0.3M8.4M3.33M
2026-04-155.31%0.4M7.0M4.62M
2026-03-317.67%0.5M6.2M4.60M
2026-03-132.03%0.1M5.5M1.36M
2026-02-272.39%0.1M5.5M1.33M
2026-02-131.68%0.1M5.5M1.32M
2026-01-3018.44%1.0M5.5M1.27M
2026-01-151.58%0.1M5.4M45.97K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-03SCHEDULE 13G/ASEC
2026-10-098-KCurrent report2026-10-05SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-08-31EFFECTEffectiveness filing by commission orderSEC
2026-08-278-KCurrent report2026-08-21SEC
2026-08-24S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-13S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-234Statement of changes in beneficial ownership of securities2026-07-22SEC
2026-07-233Initial statement of beneficial ownership of securities2026-07-22SEC
2026-07-238-KCurrent report2026-07-19SEC
2026-07-228-KCurrent report2026-07-22SEC
2026-07-22SCHEDULE 13D/ASEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-06-248-KCurrent report2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-03EFFECTEffectiveness filing by commission orderSEC
2026-06-01CORRESPSEC
2026-05-29UPLOADUpload SubmissionSEC
2026-05-274Statement of changes in beneficial ownership of securities2026-05-26SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-072.03K100
2026-0617.75K200
2026-0558.15K400
2026-040000
2026-0300116.07K2
2026-020019.68K1
2026-010093.91K7
2025-120080.08K9
2025-1100104.46K6

Institutional holders

Manager% owned
Sio Capital Management, LLC6.67%
VANGUARD CAPITAL MANAGEMENT LLC1.08%
Waverly Advisors, LLC0.45%
Ashton Thomas Private Wealth, LLC0.35%
Keel Point, LLC0.14%
NORTHERN TRUST CORP0.14%
VANGUARD FIDUCIARY TRUST CO0.13%
GEODE CAPITAL MANAGEMENT, LLC0.13%
JANE STREET GROUP, LLC0.10%
STATE STREET CORP0.09%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.84%
VANGUARD EXTENDED MARKET INDEX FUND0.22%
Fidelity Extended Market Index Fund0.16%
Fidelity Series Total Market Index Fund0.03%
Ultra-Small Company Market Fund0.02%
Fidelity Total Market Index Fund0.02%

OakChart. SER. Cached 15 minutes.